Latest News
Five-year US study highlights long-term effectiveness of ViiV Healthcare's Cabenuva
21 October 2026 - Specialist HIV company ViiV Healthcare, majority owned by GSK (LON:GSK), with Shionogi as a shareholder, on Wednesday reported five-year real-world data from the US OPERA observational cohort showing sustained viral suppression and ...
GSK wins US FDA approval for chronic hepatitis B treatment Hibsago
21 October 2026 - GSK plc (LSE: GSK) (NYSE: GSK) has received US Food and Drug Administration approval for Hibsago (bepirovirsen), a first-in-class antisense oligonucleotide for treating chronic hepatitis B in eligible adults alongside existing antiv...
Summit Therapeutics and ECOG-ACRIN launch Phase II/III trial collaboration for biliary tract cancer
21 October 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) said on Wednesday that it has partnered with the ECOG-ACRIN Cancer Research Group to evaluate ivonescimab in a registration-enabling Phase II/III clinical tria...
RxMP Therapeutics secures DARPA contract worth up to USD10.7m
21 October 2026 - RxMP Therapeutics Inc, a late pre-clinical stage therapeutics company developing novel therapies for the rapid control of hemorrhage and excessive bleeding, announced on Tuesday that it has been awarded up to USD10.7m from the US De...
TNutra launches NeuraLegend brain health supplements
21 October 2026 - Brain health supplement company TNutra announced on Tuesday the NeuraLegend system, a three-part daily brain health regimen anchored by NeuraLegend AM, which features 500 mg of Cognizin Citicoline, a patented, clinically studied cit...